MYCN and neuroblastoma: In a recent study of the super-enhancer landscapes in primary neuroblastoma patient samples, the presence of these 2 states was confirmed, and the ADRN phenotype was found to comprise 3 distinct subtypes: MYCN-amplified, non–MYCN-amplified high-risk, and non–MYCN-amplified low-risk signatures (18).